Form 4: Medpace Holdings CEO August J. Troendle Sells Shares

Medpace Holdings CEO August J. Troendle reports the sale of company stock through Medpace Investors, LLC.

Summary

• August J. Troendle, CEO of Medpace Holdings, Inc., reported the sale of common stock on February 23, 2024, and February 26, 2024.
• On February 23, 2024, 100,000 shares were sold at a weighted average price of $400.32, in transactions ranging from $396.15 to $402.50.
• On February 26, 2024, 56,928 shares were sold at a weighted average price of $402.38, in transactions ranging from $397.98 to $405.72.
• The sales were executed through Medpace Investors, LLC (MPI), where Troendle is the sole manager and controlling unit holder.
• Following the reported transactions, Troendle indirectly beneficially owns 5,233,019 shares through MPI and directly owns 806,643 shares.
• The transactions were executed pursuant to a limit order placed by MPI during an open window period.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports insider selling, which is a common occurrence. The transactions were pre-planned and executed during an open window period, suggesting routine portfolio management rather than a negative outlook on the company.

Industry Context

Insider sales are a common occurrence, and the market typically interprets them in the context of the individual's financial planning and diversification strategies. It's important to consider the size of the sale relative to the insider's total holdings.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, potentially leading to short-term price fluctuations.
• However, the disclosure provides transparency and allows investors to make informed decisions.

Key Dates